文献速递肺结节与肺癌

非小细胞肺癌的生物治疗

Biological therapies in nonsmall cell lung cancer.
PubMed 文献 · Eur Respir J · 2017-03-02

本文综述晚期非小细胞肺癌(NSCLC)的生物治疗进展:基因型导向治疗已改变EGFR突变及ALK/ROS1重排肺腺癌的治疗范式,可干预靶点(BRAF、MET、RET、NTRK1、HER2)名单持续扩展;靶向肿瘤免疫逃逸PD-1通路的药物已显示显著治疗获益,部分患者可能获得长期生存获益。

要点

  • 基因型导向治疗改变EGFR突变及ALK/ROS1重排肺腺癌的治疗范式
  • 可干预靶点扩展至BRAF、MET、RET、NTRK1和HER2
  • PD-1通路药物在晚期NSCLC显示显著获益,部分患者或获长期生存

核心结论

  • 生物治疗改善了晚期NSCLC的生存结局。
  • 基因型导向治疗改变了EGFR突变及ALK/ROS1重排肺腺癌的治疗范式。
  • 靶向PD-1通路的药物在本病中显示显著治疗获益,不可忽视的一部分患者可能获得长期生存获益。

主要发现

  • 可干预且有临床可操作性的靶点名单持续扩展,包括BRAF、MET、RET、NTRK1和HER2。
  • 对癌症免疫逃逸机制的认识逐步加深,并预见了在免疫检查点层面有效规避的途径。
  • 靶向肿瘤免疫逃逸PD-1通路的药物在晚期NSCLC中显示显著治疗获益。

临床怎么用

  • 晚期NSCLC管理需多学科协作。
  • 生物治疗应围绕基因型导向治疗与免疫检查点抑制剂展开。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biological therapies have improved survival outcomes of advanced-stage nonsmall cell lung cancer (NSCLC). Genotype-directed therapies have changed treatment paradigms of patients with EGFR-mutant and ALK/ROS1-rearranged lung adenocarcinomas, and the list of druggable targets with demonstrated clinical actionability (BRAF, MET, RET, NTRK1 and HER2) continues to expand. Furthermore, we have incrementally understood the mechanisms of cancer immune evasion and foresee ways to effectively circumvent them, particularly at the immune checkpoint level. Drugs targeting the tumour immune-evasive PD-1 pathway have demonstrated remarkable treatment benefits in this disease, with a non-negligible fraction of patients potentially receiving long-term survival benefits. Herein, we briefly discuss the role of various medical disciplines in the management of advanced-stage NSCLC and review the most relevant biological therapies for this disease, with particular emphasis in genotype-directed therapies and immune checkpoint inhibitors.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, et al. Biological therapies in nonsmall cell lung cancer. Eur Respir J. 2017. PMID: 28254765. doi:10.1183/13993003.01520-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。